Immunocore Holdings (IMCR) EPS (Weighted Average and Diluted) (2023 - 2026)
Immunocore Holdings' (IMCR) quarterly EPS (Weighted Average and Diluted) came in at $0.25 in Q1 2026, up 150.0% year-on-year from $0.1 in Q1 2025, and up 141.67% quarter-over-quarter from -$0.6 in Q4 2025.
Immunocore Holdings (IMCR) EPS (Weighted Average and Diluted) (2023 - 2026) Analysis & Trends
Immunocore Holdings has disclosed EPS (Weighted Average and Diluted) across 4 years of filings, most recently posting $0.25 for Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at $0.25, up 150.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$0.55 (down 27.91% YoY), and the FY2025 annual result was -$0.71, up 30.39% from the prior year.
- EPS (Weighted Average and Diluted) came in at $0.25 for Q1 2026 at Immunocore Holdings, up from -$0.6 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.25 in Q1 2026 to a low of -$0.6 in Q4 2025.
- The 4-year median for EPS (Weighted Average and Diluted) is -$0.23 (2024), against an average of -$0.2.
- Across the five-year window, EPS (Weighted Average and Diluted) surged 750.0% in 2024 and tumbled 102.07% in 2025, its largest moves.
- Immunocore Holdings' EPS (Weighted Average and Diluted) stood at -$0.4 in 2023, then decreased by 17.5% to -$0.47 in 2024, then fell by 27.66% to -$0.6 in 2025, then surged by 141.67% to $0.25 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at $0.25 (Q1 2026), -$0.6 (Q4 2025), and -$0.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 2 | Belite Bio | 55,234.00 Bn | 55,234.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,823.14 Bn | 17,823.14 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,624.50 Bn | 3,624.21 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,745.73 Bn | 1,745.73 Bn | - | 0.00 |
| 6 | Evaxion A | 1,540.85 Bn | 1,540.84 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 112.57 Bn | 105.33 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 93.46 Bn | 93.46 Bn | - | -0.61 |
| 10 | Immunocore Holdings | 1.46 Bn | 616.35 Mn | 106.24 Mn | 0.25 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.25 |
| Dec 31, 2025 | -0.60 |
| Sep 30, 2025 | 0.00 |
| Jun 30, 2025 | -0.20 |
| Mar 31, 2025 | 0.10 |
| Dec 31, 2024 | -0.47 |
| Sep 30, 2024 | 0.17 |
| Jun 30, 2024 | -0.23 |
| Mar 31, 2024 | -0.49 |
| Dec 31, 2023 | -0.40 |
| Sep 30, 2023 | 0.02 |
| Jun 30, 2023 | -0.35 |
| Mar 31, 2023 | -0.40 |